Health
New Obesity Drug Shows Promising Results
An investigational obesity drug from Eli Lilly has shown major weight loss in late-stage clinical trials, helping patients lose up to 30 percent of their body weight. The once-weekly injection met the primary endpoint and could offer new treatment options for obesity.
Coverage timeline — 1 article
The Hill
An investigational obesity drug from Eli Lilly cleared important endpoints in a late-stage trial, the company said Thursday, by helping patients lose up to 30 percent of their body weight. Lilly said that a once-weekly injection of retatrutide met the primary endpoint in a phase 3 clinical trial, a
2026-05-21 19:04 UTC